Loading…
Loading…
EQUITY / NASDAQ · XNMS
Anbio Biotechnology Ltd
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →01/01/2025 – 12/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗6.49 USD · 16.9369%
Observed: Oct 2, 2026, 8:30 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 5.55 USD · Volume 27,380
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
01/01/2025 – 12/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 8,646,844 USD | 8,185,146 USD | +5.64% |
| Operating profit | 5,767,740 USD | 1,995,367 USD | +189.06% |
| Net income | 6,403,463 USD | 2,372,842 USD | +169.86% |
| Operating cash flow | -6,739,075 USD | 2,080,387 USD | -423.93% |
| Cash and cash equivalents | 7,766,738 USD | 11,760,859 USD | -33.96% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2024 / Year end01/01/2024 – 12/31/2024ConsolidatedUnits · USD | 2023 / Year end01/01/2023 – 12/31/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 7,766,738 USD | 11,760,859 USD | — |
| Financing cash flowCash flow statement | 6,947,450 USD | -344,605 USD | -42,835 USD |
| Gross profitIncome statement | 7,543,162 USD | 5,885,384 USD | 3,360,869 USD |
| Investing cash flowCash flow statement | -4,202,496 USD | 337,101 USD | 1,730,173 USD |
| Net incomeIncome statement | 6,403,463 USD | 2,372,842 USD | 2,253,709 USD |
| Operating cash flowCash flow statement | -6,739,075 USD | 2,080,387 USD | 898,367 USD |
| Operating profitIncome statement | 5,767,740 USD | 1,995,367 USD | 1,960,929 USD |
| RevenueIncome statement | 8,646,844 USD | 8,185,146 USD | 6,711,990 USD |
| Total assetsBalance sheet | 30,242,859 USD | 18,921,784 USD | — |
| Total equityBalance sheet | 30,155,023 USD | 17,191,550 USD | 14,818,708 USD |
| Total liabilitiesBalance sheet | 87,836 USD | 1,730,234 USD | — |
| Report source | Open report ↗ Published: 04/07/2026 | Open report ↗ Published: 04/07/2026 | Open report ↗ Published: 04/07/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.